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Summary Objectives: To compare the effects of addition of montelukast or
salmeterol to inhaled corticosteroids (ICS) on the response to rescue beta2-agonist
use after exercise-induced bronchoconstriction.
Methods: A double-blind, placebo-controlled study was performed at 16 centers in
the United States. Patients with asthma (n ¼ 122; ages 15–58) whose symptoms were
uncontrolled on low-dose inhaled fluticasone and who had a history of exercise-
induced worsening of asthma were randomized to receive either montelukast (10mg
once daily), salmeterol (50 mg twice daily), or placebo for 4 weeks. Standardized
spirometry after exercise challenge and beta2-agonist rescue was performed at
baseline, week 1 and 4.
Results: Maximum achievable forced expiratory volume in 1 s (FEV1) percent
predicted after rescue beta2-agonist improved in the montelukast (þ 1.5%) and
placebo (þ 1.2%) groups at 4 weeks, but diminished in the salmeterol (3.9%) group
(Po0:001). Although pre-exercise FEV1 was greatest with salmeterol (P ¼ 0:10),
patients taking montelukast had significantly greater protection from an exercise-
induced decrease in FEV1 than those taking salmeterol (Po0:001). Both the
magnitude and rate of rescue bronchodilation were greater with montelukast
compared with salmeterol (Po0:001). Five minutes after rescue beta2-agonist, 92%
of patients taking montelukast and 68% of those taking placebo had recovered to
pre-exercise levels, whereas only 50% of those taking salmeterol had recovered to
pre-exercise levels.
Conclusion: In patients whose asthma symptoms remain uncontrolled using ICS,
addition of montelukast permits a greater and more rapid rescue bronchodilation
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with a short-acting beta2-agonist than addition of salmeterol and provides
consistent and clinically meaningful protection against exercise-induced broncho-
constriction.
& 2004 Elsevier Ltd. All rights reserved.
Introduction
When asthma control is incomplete on low doses of
inhaled corticosteroids (ICS), increasing the dose
results in only marginal improvement in efficacy
and may increase side effects.1–3 Current guide-
lines recommend optimizing asthma control by
adding another class of therapy, such as the long-
acting beta2-agonists (LABA) or leukotriene recep-
tor antagonists (LTRA), to ICS.4,5 Even when asthma
symptoms are controlled, episodic worsening may
occur after exposure to various asthma-specific
triggers, such as exercise, allergen, and cold dry
air. These episodes are often treated with short-
acting beta2-agonist (SABA) rescue therapy. An
add-on therapy to ICS that provides sustained
bronchoprotection and permits a robust response
to the bronchodilating effects of rescue medica-
tion, when needed, would fulfill an important
medical need.
Both montelukast, an orally active, selective
cysteinyl LTRA, and salmeterol, a LABA, have
demonstrated efficacy in adults with persistent
asthma. Bronchoprotection with montelukast is
present at 1 h6 and persists at the end of the dosing
interval without the development of tolerance
during 12 weeks of treatment.7 Although salmeter-
ol provides significant initial bronchoprotection
against a variety of direct and indirect stimuli,
the magnitude of protection decreases with chronic
use. Loss of bronchoprotection may begin within a
few days to 1 week of treatment with a LABA.8,9 In
addition, chronic administration of salmeterol may
diminish the acute bronchodilating effect of a
SABA.10–14
The current study was designed to compare the
effects of 4 weeks of treatment with montelukast
with that of salmeterol on the responsiveness after
exercise challenge to rescue bronchodilation with a
SABA in asthma patients already receiving ICS. It
was hypothesized that montelukast would permit a
better rescue bronchodilation response to beta2-
agonist administered after an exercise challenge-
induced exacerbation and would demonstrate an
advantage in protecting against exercise-induced
bronchoconstriction (EIB) when compared with
salmeterol.
Methods
Study design
This was a multicenter, randomized, parallel-
group, double-blind study consisting of a 2-week,
double-placebo period (baseline period) and a 4-
week treatment period. A placebo group was
included in the treatment period to demonstrate
that both active treatment arms produced im-
provements in the outcomes measured. The study
was conducted at 16 centers in the United States.
The protocol was approved by a central institu-
tional review board, and written informed consent
was obtained from each patient before completing
any study procedures. Exercise challenge–rescue
procedures were completed at baseline, week 1
and 4.
Inclusion and exclusion criteria
Asthma patients aged between 15 and 45 years old,
with at least a 1-year history of asthma currently
uncontrolled on ICS for at least 2 months, were
enrolled. Asthma treatment at the time of rando-
mization included only SABA and ICS. Patients were
eligible for randomization if they had documenta-
tion of EIB within the past year showing a decrease
in forced expiratory volume in 1 s (FEV1) of at least
15% while receiving ICS (or 20% while not on ICS), an
FEV1 of at least 70% of the predicted value at rest,
and at least a 12% increase in FEV1 after beta2-
agonist administration (demonstrated once during
the baseline period). All patients were required to
have needed beta2-agonist for more than 3 days
per week during the baseline period for treatment
of symptoms, indicating the need for additional
therapy. Patients with either recent upper respira-
tory infection (within 3 weeks) or emergency care
or hospitalization for asthma within the past 3
months were excluded. Systemic corticosteroids
were not allowed for 1 month before the first study
visit and throughout the study. With the exception
of ICS, patients were required to stop other anti-
asthma therapy 2 weeks before the first study visit.
Inhaled beta2-agonist for symptomatic relief of
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asthma and short-acting antihistamines were per-
mitted. Patients who needed oral corticosteroid
treatment or any additional treatment for asthma
symptoms were discontinued from the study.
Study treatment
All patients received open-label fluticasone
(1 inhalation of dry powder inhaler 100 mg twice
daily) during the baseline period and continued this
treatment for the duration of the study. Eligible
patients were randomly assigned, according to a
blinded computer-generated allocation schedule,
to receive either montelukast sodium (10-mg tablet
once daily in the evening), salmeterol xinafoate
(50-mg aerosol inhalation twice daily), or placebo.
Each patient took one tablet daily (active or
matching placebo) and one inhalation twice daily
(active or matching placebo) for both the baseline
(placebo tablet and placebo inhaler) and treatment
periods.
Evaluations
Challenge–rescue procedures were completed at
baseline, week 1 and 4. Patients were instructed to
take an evening dose of study tablet (15–17 h
previous) and a morning dose of study inhaler (3–5 h
previous) before the procedure. Patients exercised
for 6min on a treadmill, while inhaling room-
temperature dry air through a face mask, at a
workload that increased heart rate to 80% to 90% of
the individual’s age-predicted maximum. The work-
load required to achieve this target heart rate was
used in all procedures.
Pre-exercise spirometry was performed before
each challenge–rescue procedure. Pre-exercise
FEV1 (mean of the FEV1 values at 20 and 5min
before exercise) had to be X70% of the predicted
value for the procedure to be performed. Serial
spirometry was measured immediately after ex-
ercise and then at 5, 10, and 15min. Beta2-agonist
rescue (2 puffs of albuterol, 180 mg total) was
administered, and serial spirometry was performed
5, 10, 15, and 30min later. A second beta2-agonist
rescue (2 puffs of albuterol, 180 mg total) was
administered, and spirometry was performed again
30min later. At baseline and week 4, patients
completed the clinic exercise-assessment question-
naire (CEAQ)15 to describe the degree of their
symptoms immediately after exercise, 10min after
exercise, and 10min after the first administration
of rescue beta2-agonist. The CEAQ was adminis-
tered by the study coordinator and consisted of
questions about shortness of breath, wheezing, and
chest tightness graded on a 7-point scale. Addi-
tional beta2-agonist rescue was permitted outside
of the protocol-required timepoints for distressing
symptoms at the discretion of the investigator, but
remaining spirometry maneuvers in those sets were
not completed.
Spirometry was performed according to American
Thoracic Society acceptability and reproducibility
criteria16 using a standard spirometer (KoKo Spi-
rometer, PDS Instrumentation, Louisville, CO).
Patients were required to withhold the use of
inhaled beta2-agonist for at least 6 h before the
visit. All spontaneously reported adverse experi-
ences were recorded at each visit during the
double-blind period.
Based on the serial spirometry measurements of
FEV1, the pre-exercise level, minimum level after
exercise, and maximum level after rescue beta2-
agonist were determined. Exercise-induced exacer-
bation of asthma was defined as the percentage
difference between average pre-exercise and mini-
mum postexercise FEV1 values. Rescue bronchodi-
lation was defined as the percentage difference
between average pre-exercise and maximum post-
rescue beta2-agonist FEV1 values. The time-to-
recovery to pre-exercise FEV1 was defined as the
time needed to reach pre-exercise levels of FEV1
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Figure 1 Challenge–rescue procedure endpoints. The
pre-exercise, postexercise minimum, postrescue beta2-
agonist 1 and 2 maximum FEV1 percent predicted time
points on the graph are each connected with the
corresponding portion of the stacked bar by the dashed
arrows. The stacked bar graphs show exercise-induced
exacerbation (solid bar) and rescue bronchodilation after
the first (open bar) and second (hashed bar) beta2-
agonist administrations for each visit, as indicated.
EX¼ exercise; RA1¼first rescue albuterol administra-
tion, 15min after completion of exercise; RA2¼ second
rescue albuterol administration, 30min after first rescue
beta2-agonist administration; *primary endpoint.
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after first beta2-agonist rescue was administered;
see Fig. 1 for an illustration of endpoints.
Statistical methods
The primary objective was to determine the effect
of 4 weeks of treatment with placebo, montelu-
kast, and salmeterol on maximum FEV1 after beta2-
agonist administration. The secondary objectives
were to determine the effect of treatments on pre-
exercise FEV1, exercise exacerbation, rescue
bronchodilation, time-to-recovery to pre-exercise
FEV1 level, and average CEAQ score. The frequency
of adverse experiences also was evaluated.
For FEV1 variables, an analysis of covariance
model, including terms for treatment and baseline
covariates, was used to estimate the difference
between treatment groups for each endpoint. A
modified intention-to-treat approach was used for
efficacy analyses. For FEV1, all randomized patients
who had challenge–rescue evaluations at baseline
and during treatment were eligible for analyses.
There was no imputation of missing values, and
prior values were not carried forward. Time-to-
recovery of FEV1 was analyzed using Kaplan–Meier
time-to-event estimates with corresponding Wil-
coxon statistics. Recovery time was estimated by
linear interpolation of the two timepoints on either
side of the pre-exercise FEV1 percent predicted
value. Analysis of covariance was used to compare
the change from baseline to week 4 for the 0- and
10-min postexercise timepoints and the 10-minute
postrescue timepoint of the CEAQ. Descriptive
statistics were computed by treatment group for
patient demographics and clinical characteristics.
All statistical analyses were performed using SASs
Version 6 (SAS Institute, Inc., Cary, NC).
Results
Patients
Figure 2 shows the disposition of patients in this
study. The most common reason for disqualification
was failure to meet a 15% decrease in FEV1 with
exercise. A total of 119 patients (97.5%) completed
the 4-week, double-blind study; three patients
discontinued prematurely for the reason indicated
in Fig. 2. More women and fewer men were
enrolled in the montelukast group than in the
salmeterol or placebo groups, although this differ-
ence was not statistically significant. All other
demographic and baseline clinical characteristics
were comparable among the three treatment
groups (Table 1).
Nine patients (three from each treatment group)
were enrolled at a site noted to have irregularities
with Good Clinical Practice after the study was
completed. All analyses were performed both with
and without data from these nine patients, and
there were no meaningful differences between the
analyses. The results presented exclude data from
these nine patients.
Challenge-rescue
FEV1 values expressed as percent predicted before
and during the challenge–rescue procedures and
the degree of EIB and rescue bronchodilation at
baseline, week 1 and 4 are shown in Fig. 3 and
Table 2. At baseline, the three treatment groups
had comparable pre-exercise, minimum postexer-
cise, and maximum postalbuterol FEV1 values.
Maximum FEV1 after first beta2-agonist rescue
After 4 weeks of therapy, maximum postalbuterol
rescue FEV1 percent predicted values improved in
the montelukast and placebo treatment groups, but
diminished in the salmeterol group (þ 1.5%,
þ 1.2%, and 3.9% for montelukast, placebo, and
salmeterol, respectively; Table 2). The maximum
FEV1 in the salmeterol group was significantly less
than the maximum FEV1 in both the montelukast
(Po0:001) and placebo (Po0:001) groups. Results
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253 Patients Screened
131 Patients Entered 2-Week
Placebo/Fluticasone Run-In
122 Patients Randomized
After 2-Week
Fluticasone/Placebo Run-In
39 Patients Received
Montelukast/Fluticasone
39 Patients Received
Salmeterol/Fluticasone
44 Patients Received
Placebo/Fluticasone
36 (92.3%) Patients
Completed
4-Week Study
34 (87.2%) Patients
Completed
4-Week Study
39 (90.9%) Patients
Completed
4-Week Study
No Patients Discontinued
Study
2 (5.1%) Patients
Discontinued Study:
Clinical AE, 1 Pt Relocated
1 (2.3%) Patient
Discontinued Study:
1 Protocol Deviation
3 Patients (7.7%) Excluded
Due To Deviations From
Good Clinical Practice
Standards
3 Patients (7.7%) Excluded
Due To Deviations From
Good Clinical Practice
Standards
3 Patients (6.8%) Excluded
Due To Deviations From
Good Clinical Practice
Standards
Figure 2 Patient disposition. AE¼ adverse experience.
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obtained after 1 week of therapy had similar values
of þ 1.7%, þ 1.7%, and 3.1% for montelukast,
placebo, and salmeterol, respectively. The treat-
ment effects observed between montelukast and
placebo were not significantly different. The
maximum FEV1 values obtained after the second
beta2-agonist rescue (Table 2) are consistent with
those seen after the first rescue.
Pre-exercise FEV1
There were small increases compared with baseline
values in pre-exercise FEV1 percent predicted for
salmeterol-treated patients at weeks 1 and 4, but
not in patients receiving either montelukast or
placebo (Table 2). The mean change from baseline
in pre-exercise FEV1 percent predicted was sig-
nificantly greater in the salmeterol treatment
group compared to the montelukast treatment
group at weeks 1 and 4 (P ¼ 0:010) and to the
placebo group at week 1 (Po0:001). There was no
significant difference between montelukast and
placebo treatment groups with respect to pre-
exercise FEV1 percent predicted values.
Exercise-induced exacerbation
Mean baseline measures of EIB were generally
comparable among the montelukast, salmeterol,
and placebo groups (Table 2). The improvement
from baseline to week 4 was 5.5%, 3.1%, and
0.5%, respectively. Compared with placebo, mon-
telukast significantly decreased EIB at week 4
(P ¼ 0:008). The treatment effects observed be-
tween salmeterol and placebo and between salme-
terol and montelukast were not significantly
different. At week 1, the change from baseline in
EIB was 6.4%, 1.2%, and 0.6% for the mon-
telukast, salmeterol, and placebo groups, respec-
tively. The improvement with montelukast was
significantly greater than that with either salme-
terol (P ¼ 0:004) or placebo (Po0:001). The treat-
ment effect observed between salmeterol and
placebo at week 1 was not significantly different.
Rescue bronchodilation
Mean baseline measures of rescue bronchodilation
were generally comparable among the montelu-
kast, salmeterol, and placebo groups after the first
and second beta2-agonist rescues (Table 2). The
mean changes from baseline to week 4 in rescue
bronchodilation after the first beta2-agonist rescue
were þ 1.6%, 7.9%, and 0.3% for the montelu-
kast, salmeterol, and placebo treatment groups,
respectively. The loss in rescue bronchodilation
seen with salmeterol was significant compared with
montelukast and placebo (Po0:001). The treat-
ment effects observed between montelukast and
placebo were not significantly different. The
analyses of rescue bronchodilation after the second
beta2-agonist rescue were consistent with those
observed after rescue 1. Similarly, the results
obtained at week 1 were consistent with those
obtained at week 4.
Time-to-recovery
After 4 weeks of therapy, montelukast permitted
significantly faster rescue with beta2-agonist com-
pared with both salmeterol (P ¼ 0:005) and placebo
(P ¼ 0:036; Fig. 4). Patients treated with salmeter-
ol had slower beta2-agonist rescue response com-
pared with those taking placebo, although the
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Table 1 Demographic and Baseline Clinical Characteristics.
Montelukast/
fluticasone
(n ¼ 39)
Salmeterol/
fluticasone
(n ¼ 39)
Placebo/
fluticasone
(n ¼ 44)
Age (years), mean (range) 33.3 (15–58) 30.0 (15–47) 30.6 (15–56)
Men (%) 28.2 41.0 45.5
Women (%) 71.8 59.0 54.5
Caucasian (%) 94.9 92.3 95.5
Black (%) 0.0 2.6 2.3
Hispanic (%) 5.1 5.1 2.3
Asthma duration (years), mean7SD 17.4711.1 19.7712.0 18.9711.0
Pre-exercise FEV1 (L), mean7SD 3.170.6 3.270.7 3.170.6
Pre-exercise FEV1 (% predicted), mean7SD 87.5710.4 88.179.5 87.8710.6
Maximum % decrease in FEV1 13.8711.8 13.7713.4 14.5714.7
Reversibility (%)7SD 16.777.4 19.777.3 18.278.9
Total beta2-agonist use (puffs/day)7SD 2.971.5 3.371.9 3.172.2
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difference was not significant. At week 4, 92%, 50%,
and 68% of patients in the montelukast, salmeterol,
and placebo groups, respectively, recovered to pre-
exercise FEV1 levels 5min after rescue with beta2-
agonist. By 30min postrescue, the percentages
were 100%, 71%, and 89% of patients in the
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Figure 3 FEV1 during the challenge-rescue procedure. Graphs show the mean FEV1 percent predicted and standard
error after exercise challenge and beta2-agonist rescue at baseline (solid circle, solid line), week 1 (solid triangle,
dashed line), and week 4 (open square, solid line). The corresponding stacked bar graphs show exercise-induced
exacerbation (solid bar), rescue bronchodilation after the first (open bar), and second (hashed bar) beta2-agonist
administrations for each visit, as indicated below each bar. Change from baseline analyses: 2Po0:010 versus
montelukast and placebo at week 1 and 4; 1Po0:01 versus montelukast at week 4.
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Table 2 Challenge-rescue efficacy values.
Montelukast/fluticasone Salmeterol/fluticasone Placebo/fluticasone
Baseline
(n ¼ 36)
Week 1
(n ¼ 36)
Week 4
(n ¼ 36)
Baseline
(n ¼ 36)
Week 1
(n ¼ 35)
Week 4
(n ¼ 34)
Baseline
(n ¼ 41)
Week 1
(n ¼ 41)
Week 4
(n ¼ 38)
Maximum FEV1 (%
predicted) after first
beta2-agonist rescue,
mean (SD)
94.7 (11.3) 96.3 (12.6) 95.8 (11.8) 96.6 (10.6) 93.9 (10.7) 92.5 (11.9) 95.6 (12.7) 96.8 (11.7) 95.8 (12.2)
Maximum FEV1 (%
predicted) after second
beta2-agonist rescue,
mean (SD)
96.0 (11.5) 97.5 (12.4) 97.0 (11.9) 98.0 (9.9) 96.5 (10.4) 95.2 (10.6) 97.5 (10.2) 99.7 (11.1) 98.8 (10.3)
Pre-exercise FEV1 (%
predicted), mean (SD)
86.9 (10.3) 86.9 (11.9) 86.6 (11.0) 88.0 (9.7) 91.4 (9.6) 91.2 (10.1) 87.2 (10.7) 86.3 (10.9) 87.8 (10.0)
Exercise-induced
exacerbation (maximum
percent fall from pre-
exercise FEV1), mean
(SD)
12.9 (11.3) 6.9 (7.1) 7.7 (8.1) 12.9 (12.2) 12.3 (11.0) 10.5 (10.0) 14.9 (15.0) 13.8 (12.0) 13.6 (15.2)
Rescue bronchodilation
(maximum percent rise
from pre-exercise FEV1
after first beta2-agonist
rescue), mean (SD)
9.2 (7.2) 11.3 (10.8) 10.9 (8.5) 10.0 (6.4) 2.7 (5.2) 1.7 (9.5) 10.0 (11.3) 12.5 (8.2) 9.3 (9.8)
Rescue bronchodilation
(maximum percent rise
from pre-exercise FEV1
after second beta2-
agonist rescue), mean
(SD)
10.7 (7.8) 12.7 (11.0) 12.3 (9.1) 12.1 (6.4) 5.6 (4.6) 4.7 (7.6) 13.2 (8.9) 16.0 (8.6) 12.9 (7.3)
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montelukast, salmeterol, and placebo groups,
respectively. Similar results were observed after 1
week of therapy.
Clinic exercise-assessment questionnaire
At baseline, all patients noted the highest degree
of symptoms immediately after exercise and
showed an improvement in CEAQ score 10min
later, with further improvement after rescue
beta2-agonist administration. After 4 weeks of
treatment, significant differences in the mean
CEAQ score immediately after exercise and 10min
after exercise (Fig. 5) were found between patients
in the montelukast and placebo groups (Po0:020).
In addition, patients treated with placebo had a
marked improvement in their symptoms after
beta2-agonist rescue, unlike the patients in the
salmeterol group.
Safety
Both montelukast and salmeterol were generally
well tolerated. There were no serious clinical
adverse experiences. One patient treated with
salmeterol discontinued because of a clinical
adverse event (intervertebral disc displacement).
No patients experienced an asthma attack during
the study.
Discussion
Guidelines for the treatment of persistent asthma
recommend that daily controller therapy with ICS
and additional agents, if needed, be used to
minimize the impact of the disease. These guide-
lines further recommend that SABA therapy be
available ‘‘as needed’’ to treat exacerbations.4,5
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Figure 5 CEAQ score. The mean CEAQ score and 95% confidence interval for the placebo (triangle), montelukast
(square), and salmeterol (circle) groups at baseline and visit 4. Po0:02 montelukast versus placebo; Po0:05
montelukast versus placebo.
Figure 4 Time-to-recovery to pre-exercise FEV1. Cumulative percentage of patients whose FEV1 returned to the pre-
exercise level at baseline (solid line), week 1 (dotted line), and week 4 (broken dashed line). 1Po0:001 versus
salmeterol at week 1; 2P ¼ 0:005 versus salmeterol at week 4; P ¼ 0:005 versus salmeterol at week 4.
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The current study demonstrated that patients
treated with montelukast had significantly greater
response to beta2-agonist compared with patients
taking salmeterol at 1 and 4 weeks of therapy. This
finding was a result of a decrease in the level and
rapidity of rescue bronchodilation in patients
taking salmeterol. Furthermore, patients receiving
montelukast had a significantly greater attenuation
of EIB compared with those taking placebo,
whereas patients taking salmeterol did not. These
differences were present after 1 week of treatment
and persisted over 4 weeks, consistent with
previous comparisons of montelukast and salmeter-
ol in the attenuation of EIB in patients not receiving
ICS.17,18 The findings of the current study also
confirm previously published reports that chronic
administration of LABAs decrease the effects of
SABAs in a variety of settings.9,12,19–21
Chronic stimulation of beta2-adrenergic recep-
tors is known to cause downregulation of airway
smooth muscle receptor numbers and uncoupling of
intracellular signaling.22–24 This, in turn, results in
a decreased sensitivity of the beta2-adrenergic
receptor to further stimulation by the agonist,
including a SABA.25,26 Tachyphylaxis may occur
even in the presence of concomitantly adminis-
tered ICS.8,27,28 In addition, salmeterol is known to
be a partial agonist29 with a long receptor
occupancy time, which could have prevented
beta2-agonist access to the receptors. Because
the beta2-agonist rescue was performed at the
time of peak salmeterol concentration during
chronic dosing, both of these phenomena probably
contributed to the decrease in response to beta2-
agonist rescue in the current study.
In contrast, montelukast has no known effect on
the function of beta2 receptors. Previous studies
have consistently shown an additive bronchodilat-
ing effect of beta2-agonist in patients treated with
montelukast,30,31 suggesting that airway smooth
muscle tone is maintained by both leukotriene and
adrenergic stimulation. Thus, the preservation of
full bronchodilator effect with beta2-agonist in
patients treated with montelukast is not surprising.
Although the patients in this study had moderate
asthma, they had relatively mild exercise-induced
worsening of airflow at baseline, despite a history
of at least a 15% decrease in FEV1 in the previous
year. The differences between the postrescue
beta2-agonist maximum FEV1 values among the
treatment groups, although statistically significant,
were small. Despite these small differences in
airway function, patients perceived differences in
postexercise symptoms, as demonstrated by the
CEAQ responses, 10min before and 10min after
rescue beta2-agonist was given, suggesting that
these differences are clinically important. Patients’
perceptions of impairment from EIB exacerbations
may be affected by the duration of the exacerba-
tion. Approximately 20% of patients treated with
salmeterol failed to return to their pre-exacerba-
tion baseline status 30min after rescue beta2-
agonist administration. Thus, the significantly
slower bronchodilator response noted in patients
on salmeterol may have contributed to their
perceptions. In addition, patients may be better
able to perceive changes (i.e., improvements)
rather than absolute levels in their airway
function.32
Salmeterol demonstrated a pre-exercise bronch-
odilation effect that persisted during the 4 weeks
of treatment, consistent with previous findings.11,33
However, the level of maximum FEV1 achieved with
salmeterol was less than that seen with beta2-
agonist at baseline. After 1 week of salmeterol
therapy, patients were unable to obtain the
maximal bronchodilator response to beta2-agonist
that was observed before salmeterol therapy.
Previous studies comparing salmeterol and monte-
lukast as add-on therapy to ICS have not evaluated
responsiveness to rescue beta2-agonist as an end-
point. Nelson and colleagues34 examined both
agents added to inhaled fluticasone for 12 weeks
and found that salmeterol provided greater im-
provement in peak expiratory flow and reduction in
the frequency of rescue beta2-agonist use; how-
ever, they did not measure airflow during exacer-
bations or after rescue treatment. Rescue
bronchodilation after methacholine-induced ex-
acerbation has been investigated in patients
receiving salmeterol or formoterol.9,35 van der
Woude and colleagues9 found that after 4 weeks
of treatment, patients who had taken either drug
had significantly less and slower rescue bronchodi-
lation compared with those treated with placebo,
similar to the findings in the current study. Lip-
worth et al.35 found that treatment with formoter-
ol led to tachyphylaxis to bronchoprotection
against methacholine challenge after 2 weeks of
therapy, but the bronchodilator effects were
maintained during this period.
Both montelukast and salmeterol were well
tolerated in this study. There were no significant
between-group differences in the frequency of
clinical or laboratory adverse experiences, and no
patient experienced an asthma attack during this
short study. Montelukast is a potential companion
therapy for patients with persistent asthma who
are already being treated with ICS. In patients who
also have a component of EIB, montelukast may
have an advantage over LABA add-on therapy
because it can provide persistent attenuation of
ARTICLE IN PRESS
1060 W. Storms et al.
the exercise-induced decrease in FEV1, and it has
an additive effect with rescue SABA therapy.
Further, this study highlights the importance of
evaluating the consequence of chronic asthma
therapy on the effect of ‘‘as-needed’’ rescue
bronchodilator treatment, an important aspect of
asthma care.
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